Submit an abstract
The symposium agenda is currently in progress and we welcome proposals for oral and poster presentation on THERAPEUTIC APPLICATIONS AND DELIVERY STRATEGIES of synthetic oligonucleotides, including:
>Antisense and catalytic oligonucloetides
>Toxicity and pharmacokinetics
We particularly encourage final year doctoral students and early/mid career postdoctoral researchers/junior group leaders to submit oral abstracts, as we believe this event will provide their research an excellent exposure, critical analysis by attending senior researchers and new career opportunities.
Please note the following abstract submission policies.
-o- The person submitting the abstract will be the first or the last author and will receive all communications regarding their abstract.
-o- Please use the provided ABSTRACT TEMPLATE for drafting your abstract and upload all information as a single file using the link below. Save your abstract file, e.g., for Dr David Jones, as Jones-Oligo17. Abstracts as scanned images or in PDF will not be considered.
-o- Abstract must not exceed 2000 characters with spaces (excluding title, authorship and contact/email information). Longer abstracts will not be considered.
-o- Do not include subheadings, paragraphs, images or references.
-o- Acceptance of an abstract does not automatically imply commitment to financial support for the presenter. Limited financial support is available for invited academic speakers only. Industrial and non-invited speakers/poster presenters are expected to register as fee-paying delegates.
-o- You may submit your abstract for pre-approval but your registration fee must be paid in full and your abstract received by the advertised deadlines for it to be formally accepted for presentation.
Before completing the registration form please ensure that your browser and computer settings allow ‘form submission’ and ‘file upload’. We strongly recommend that after submitting your form you send us a brief email on Oligomer@LPMHealthcare.com to inform us of the submission.